The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Overcoming cellular barriers for RNA therapeutics
Abstract
RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary defenses that have kept RNAs on the outside of cells from invading the inside of cells. Overcoming the lipid bilayer to deliver RNA into cells has remained the major problem to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun to penetrate this evolutionary armor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As an emerging programmable gene interference technique, siRNA offers high specificity and flexibility in targeting the diseased human genome [236].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [236]
In the citing paper
“Many obstacles still exist despite the rise in studies on delivery platforms, including toxicity and the precise distribution of mRNA to extrahepatic organs [13, 14].”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [13]
In the citing paper
“Independent of the administration route, several evolutionary barriers are designed to prevent any intrusion of foreign nucleic acids and thus limit the delivery of exogenous mRNA [74].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [74]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“With the development of chemical modifications on RNA molecules, modified siRNA are reported to remain intact for long durations under circulation, which provides the possibility of delivering siRNA without the shielding of nanoparticles.[19, 75, 76]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
DNA interrogation by the CRISPR RNA-guided endonuclease Cas9
Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C., & Doudna, J. A. (2014) · Nature · doi:10.1038/nature13011 · Cited by 1,822
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
Polymenidou, M., Lagier-Tourenne, C., Hutt, K. R., Huelga, S. C., Moran, J., Liang, T. Y., Ling, S.-C., Sun, E., Wancewicz, E., Mazur, C., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2779 · Cited by 1,335
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Morpholino Antisense Oligomers: Design, Preparation, and Properties
Summerton, J. E., & Weller, D. D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,137
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,027
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 904
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 882
Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez‐Berestein, G., & Sood, A. K. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2966 · Cited by 834
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Peptide nucleic acids (PNA). Oligonucleotide analogs with an achiral peptide backbone
Egholm, M., Buchardt, O., Nielsen, P. E., & Berg, R. H. (1992) · Journal of the American Chemical Society · doi:10.1021/ja00031a062 · Cited by 739
A prudent path forward for genomic engineering and germline gene modification
Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R. A., Church, G., Corn, J. E., Daley, G. Q., Doudna, J. A., Fenner, M., et al. (2015) · Science · doi:10.1126/science.aab1028 · Cited by 733
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown
Wittrup, A., Ai, A., Liu, X., Hamar, P., Trifonova, R., Charisse, K., Manoharan, M., Kirchhausen, T., & Lieberman, J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3298 · Cited by 693
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Eckstein, F. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0506 · Cited by 684
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse modelPreprint
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 680
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles
Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520244113 · Cited by 624
Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy
Chiriboga, C. A., Swoboda, K. J., Darras, B. T., Iannaccone, S. T., Montes, J., Vivo, D. C. D., Norris, D. A., Bennett, C. F., & Bishop, K. M. (2016) · Neurology · doi:10.1212/wnl.0000000000002445 · Cited by 613
Prakash, T. P., Graham, M., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 588
Lagier‐Tourenne, C., Baughn, M. W., Rigo, F., Sun, S., Liu, P., Li, H., Jiang, J., Watt, A. T., Chun, S. J., Katz, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318835110 · Cited by 585
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582
Maxfield, F. R. (1982) · The Journal of Cell Biology · doi:10.1083/jcb.95.2.676 · Cited by 570
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J. E., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 559
Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes
Wang, Y., Juranek, S., Li, H., Sheng, G., Wardle, G. S., Tuschl, T., & Patel, D. J. (2009) · Nature · doi:10.1038/nature08434 · Cited by 549
Jiang, J., Zhu, Q., Gendron, T. F., Saberi, S., McAlonis-Downes, M., Seelman, A., Stauffer, J. E., Jafar-nejad, P., Drenner, K., Schulte, D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.006 · Cited by 536
Matsukura, M., Shinozuka, K., Zon, G., Mitsuya, H., Reitz, M. S., Cohen, J. S., & Broder, S. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7706 · Cited by 533
Don’t edit the human germ line
Lanphier, E., Urnov, F., Haecker, S. E., Werner, M., & Smolenski, J. (2015) · Nature · doi:10.1038/519410a · Cited by 530
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
Alter, J., Lou, F., Rabinowitz, A. H., Yin, H., Rosenfeld, J., Wilton, S. D., Partridge, T. A., & Lu, Q. L. (2006) · Nature Medicine · doi:10.1038/nm1345 · Cited by 499
The asialoglycoprotein receptor: a model for endocytic transport receptors
Spiess, M. (1990) · Biochemistry · doi:10.1021/bi00495a001 · Cited by 488
Ryter, J. M., & Schultz, S. C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7505 · Cited by 479
Robbins, M., Judge, A. D., & MacLachlan, I. (2009) · Oligonucleotides · doi:10.1089/oli.2009.0180 · Cited by 463
Stein, C. A., Hansen, J. B., Lai, J., Wu, S., Voskresenskiy, A., H⊘g, A., Worm, J., Hedtjärn, M., Souleimanian, N., Miller, P., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp841 · Cited by 360
Maeda, H., Tsukigawa, K., & Fang, J. Q. (2015) · Microcirculation · doi:10.1111/micc.12228 · Cited by 356
A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines
Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338
Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics
Lönn, P., Kacsinta, A. D., Cui, X.-S., Hamil, A. S., Kaulich, M., Gogoi, K., & Dowdy, S. F. (2016) · Scientific Reports · doi:10.1038/srep32301 · Cited by 329
Self-citationProgress Toward Synthetic Cells
Blain, J. C., & Szostak, J. W. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-080411-124036 · Cited by 323
Sehgal, A., Barros, S. A., Ivanciu, L., Cooley, B. C., Qin, J., Racie, T., Hettinger, J. L., Carioto, M., Jiang, Y., Brodsky, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3847 · Cited by 315
Efficient generation of human iPSCs by a synthetic self-replicative RNA
Yoshioka, N., Gros, E., Li, H.-R., Kumar, S., Deacon, D. C., Maron, C., Muotri, A. R., Chi, N. C., Fu, X.-D., Yu, B. D., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.06.001 · Cited by 312
Self-citationHepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Wooddell, C. I., Rozema, D. B., Hoßbach, M., John, M., Hamilton, H., Chu, Q., Hegge, J., Klein, J. J., Wakefield, D. H., Oropeza, C. E., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.31 · Cited by 291
Agrawal, S., Goodchild, J., Civeira, M. P., Thornton, A., Sarin, P. S., & Zamecnik, P. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7079 · Cited by 291
From guide to target: molecular insights into eukaryotic RNA-interference machinery
Ipsaro, J. J., & Joshua-Tor, L. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2931 · Cited by 281
Stec, W. J., Zon, G., & Egan, W. (1984) · Journal of the American Chemical Society · doi:10.1021/ja00332a054 · Cited by 278
Yu, D., Pendergraff, H. M., Liu, J., Kordasiewicz, H. B., Cleveland, D. W., Swayze, E. E., Lima, W. F., Crooke, S. T., Prakash, T. P., & Corey, D. R. (2012) · Cell · doi:10.1016/j.cell.2012.08.002 · Cited by 277
The response of mammalian cells to double-stranded RNA
Gantier, M. P., & Williams, B. R. G. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.06.016 · Cited by 273
The “Strong” RNA World Hypothesis: Fifty Years Old
Neveu, M. F., Kim, H., & Benner, S. A. (2013) · Astrobiology · doi:10.1089/ast.2012.0868 · Cited by 242
Moulton, H. M., & Moulton, J. D. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.02.012 · Cited by 229
Cuellar, T. L., Barnes, D., Nelson, C., Tanguay, J., Yu, S., Wen, X., Scales, S. J., Gesch, J., Davis, D., Smith, A. V. B., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1362 · Cited by 217
Progress Toward In Vivo Use of siRNAs-II
Rettig, G. R., & Behlke, M. A. (2011) · Molecular Therapy · doi:10.1038/mt.2011.263 · Cited by 217
Intrathecal Injections in Children With Spinal Muscular Atrophy
Haché, M., Swoboda, K. J., Sethna, N. F., Farrow-Gillespie, A. C., Khandji, A. G., Xia, S., & Bishop, K. M. (2016) · Journal of Child Neurology · doi:10.1177/0883073815627882 · Cited by 215
Meade, B. R., Gogoi, K., Hamil, A. S., Palm‐Apergi, C., van den Berg, A., Hagopian, J. C., Springer, A. D., Eguchi, A., Kacsinta, A. D., Dowdy, C. F., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3078 · Cited by 196
Self-citationRajeev, K. G., Nair, J. K., Jayaraman, M., Charissé, K., Taneja, N., O′Shea, J., Willoughby, J. L. S., Yucius, K., Nguyen, T. M., Shulga‐Morskaya, S., et al. (2015) · ChemBioChem · doi:10.1002/cbic.201500023 · Cited by 190
Liang, X., Sun, H., Shen, W., & Crooke, S. T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv143 · Cited by 184
Fletcher, S., Honeyman, K., Fall, A., Harding, P. L., Johnsen, R. D., & Wilton, S. D. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.838 · Cited by 183
Brito, L. A., Kommareddy, S., Maione, D., Uematsu, Y., Giovani, C., Scorza, F. B., Otten, G. R., Yu, D. L., Mandl, C. W., Mason, P. W., et al. (2014) · Advances in genetics · doi:10.1016/bs.adgen.2014.10.005 · Cited by 181
Sliedregt, L. A. J. M., Rensen, P. C. N., Rump, E. T., van Santbrink, P. J., Bijsterbosch, M. K., Valentijn, A. R. P. M., van der MAREL, G. A., BOOM, J. H. V., van Berkel, T. J. C., & Biessen, E. A. L. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm981078h · Cited by 139
Li, M., Tao, Y., Shu, Y., LaRochelle, J. R., Steinauer, A., Thompson, D. B., Schepartz, A., Chen, Z., & Liu, D. R. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b05694 · Cited by 136
Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell
Lönn, P., & Dowdy, S. F. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1046431 · Cited by 135
Self-citationJuliano, R. L., Ming, X., Carver, K. A., & Laing, B. M. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0463 · Cited by 135
Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells
Liu, J., Gaj, T., Yang, Y., Wang, N., Shui, S., Kim, S., Kanchiswamy, C. N., Kim, J., & Barbas, C. F. (2015) · Nature Protocols · doi:10.1038/nprot.2015.117 · Cited by 129
Wan, W. B., Migawa, M. T., Vasquez, G., Murray, H. M., Nichols, J. G., Gaus, H. J., Berdeja, A., Lee, S. S., Hart, C. E., Lima, W. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1115 · Cited by 128
Oka, N., Yamamoto, M., Sato, T., & Wada, T. (2008) · Journal of the American Chemical Society · doi:10.1021/ja805780u · Cited by 123
Stec, W. J., Karwowski, B. T., Boczkowska, M., Guga, P., Koziołkiewicz, M., Sochacki, M., Wieczorek, M. W., & Błaszczyk, J. (1998) · Journal of the American Chemical Society · doi:10.1021/ja973801j · Cited by 122
Chang, C. I., Yoo, J. W., Hong, S. W., Lee, S. E., Kang, H. S., Sun, X., Rogoff, H. A., Ban, C., Kim, S., Li, C. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.298 · Cited by 120
Eckstein, F. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00970a054 · Cited by 116
Dirin, M., & Winkler, J. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.774366 · Cited by 115
Asymmetric RNA duplexes mediate RNA interference in mammalian cells
Sun, X., Rogoff, H. A., & Li, C. J. (2008) · Nature Biotechnology · doi:10.1038/nbt.1512 · Cited by 114
A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications
Järver, P., O’Donovan, L., & Gait, M. J. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0454 · Cited by 102
Optimized siRNA-PEG Conjugates for Extended Blood Circulation and Reduced Urine Excretion in Mice
Iversen, F., Yang, C., Dagnæs‐Hansen, F., Schaffert, D., Kjems, J., & Gao, S. (2013) · Theranostics · doi:10.7150/thno.5743 · Cited by 98
Yang, B., Ming, X., Cao, C., Laing, B. M., Yuan, A., Porter, M. A., Hull-Ryde, E. A., Maddry, J. A., Suto, M. J., Janzen, W. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv060 · Cited by 98
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
Yu, R. Z., Graham, M. J., Post, N. M., Riney, S., Zanardi, T. A., Hall, S., Burkey, J., Shemesh, C. S., Prakash, T. P., Seth, P. P., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.26 · Cited by 97
A role for peptides in overcoming endosomal entrapment in siRNA delivery — A focus on melittin
Hou, K. K., Pan, H., Schlesinger, P. H., & Wickline, S. A. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.05.005 · Cited by 86
Castanotto, D., Lin, M., Kowolik, C. M., Wang, L., Ren, X., Soifer, H. S., Koch, T., Hansen, B. R., Oerum, H., Armstrong, B., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv964 · Cited by 82
Liang, X., Shen, W., Sun, H., Kinberger, G. A., Prakash, T. P., Nichols, J. G., & Crooke, S. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw144 · Cited by 79
Byrne, M., Tzekov, R. T., Wang, Y., Rodgers, A., Cardia, J. P., Ford, G., Holton, K., Pandarinathan, L., Lapierre, J., Stanney, W., et al. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2013.0148 · Cited by 78
Weidner, D. A., Valdez, B. C., Henning, D., Greenberg, S. R., & Busch, H. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00517-d · Cited by 63
Primeval cells: Possible energy-generating and cell-division mechanisms
Koch, A. L. (1985) · Journal of Molecular Evolution · doi:10.1007/bf02102359 · Cited by 62
Intracellular Localization and Routing of miRNA and RNAi Pathway Components
Ohrt, T., Muetze, J., Svoboda, P., & Schwille, P. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612798919132 · Cited by 61
Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ
Cu, Y., Broderick, K. E., Banerjee, K., Hickman, J., Otten, G. R., Barnett, S. W., Kichaev, G., Sardesai, N. Y., Ulmer, J. B., & Geall, A. J. (2013) · Vaccines · doi:10.3390/vaccines1030367 · Cited by 58
Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs
Osborn, M. F., Alterman, J. F., Nikan, M., Cao, H., Didiot, M. C., Hassler, M. R., Coles, A. H., & Khvorova, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv942 · Cited by 42
Gene-targeting pharmaceuticals for single-gene disorders
Beaudet, A. L., & Meng, L. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv476 · Cited by 38
RNA-Based Vaccination: Sending a Strong Message
Weiner, D. B. (2013) · Molecular Therapy · doi:10.1038/mt.2013.26 · Cited by 19
Cryo-electron microscopy for structure analyses of membrane proteins in the lipid bilayer
Abe, K., & Fujiyoshi, Y. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.06.001 · Cited by 17
Synthesis and Conjugation of Small Interfering Ribonucleic Neutral SiRNNs
Hamil, A. S., & Dowdy, S. F. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3112-5_1 · Cited by 13
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Rich, A. in Horizons In Biochemistry (eds. Kasha, M. & Pullman, B.) 103–126 (Academic Press, New York, 1962).
- Cummings, R. & McEver, R. in Essentials of Glycobiology. 2nd edn. (eds. Varki, A. et al.) Chapter 31 (Cold Spring Harbor (NY); Cold Spring Harbor Laboratory Press, 2009).
Cited by
Sorted by citations
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 767
Metadata
- Authors
- Dowdy, S. F.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Dowdy, Steven F
- ORCID
- Dowdy, Steven F
- Venue
- Nature Biotechnology
- Published
- 2017-02-27
- Volume
- 35
- Issue
- 3
- Pages
- 222-229
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2594133976
- Cited by
- 1,139
- References
- 105
- Citations by year
- 2026: 103 · 2025: 130 · 2024: 147 · 2023: 133 · 2022: 130 · 2021: 141 · 2020: 104 · 2019: 88 · 2018: 120 · 2017: 41
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- RNA therapeutics, RNA delivery, lipid bilayers, siRNA, microRNA, antisense oligonucleotides, aptamers, synthetic mRNA, CRISPR/Cas9
- MeSH terms
- RNAi Therapeutics, Animals, Cell Membrane, Humans, RNA, RNA Interference, Nanocapsules, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
